Sclerosis News and Research

RSS

Generic scale compares manual ability across diagnoses

Researchers have developed a generic manual ability scale unbiased by diagnosis that could allow quantitative comparisons of manual ability between diagnostic groups.

20 Nov 2012

Boston and Cincinnati Children's Hospital to learn more about how autism develops

A network of five leading medical centers, led by Cincinnati Children's Hospital Medical Center and Boston Children's Hospital, has received a five-year, $12.5 million National Institutes of Health (NIH) grant to learn more about how autism develops.

20 Nov 2012

New nanoparticle halts relapsing remitting multiple sclerosis in mouse model

In a breakthrough for nanotechnology and multiple sclerosis, a biodegradable nanoparticle turns out to be the perfect vehicle to stealthily deliver an antigen that tricks the immune system into stopping its attack on myelin and halt a model of relapsing remitting multiple sclerosis (MS) in mice, according to new Northwestern Medicine research.

19 Nov 2012

NIH-funded scientists develop new treatment to combat autoimmune disorders in mouse model

In a mouse model of multiple sclerosis (MS), researchers funded by the National Institutes of Health have developed innovative technology to selectively inhibit the part of the immune system responsible for attacking myelin-the insulating material that encases nerve fibers and facilitates electrical communication between brain cells.

18 Nov 2012

Study shows how Parkinson's spreads and leads to nerve cell death

Understanding how any disease progresses is one of the first and most important steps towards finding treatments to stop it. This has been the case for such brain-degenerating conditions as Alzheimer's disease. Now, after several years of incremental study, researchers at the Perelman School of Medicine, University of Pennsylvania have been able to piece together important steps in how Parkinson's disease (PD) spreads from cell to cell and leads to nerve cell death.

17 Nov 2012

Caution over monoclonal antibody treatment for MS

Alemtuzumab, an anti-CD52 monoclonal antibody, provides a more effective treatment for individuals with relapsing‑remitting multiple sclerosis than the immunomodulating drug interferon beta 1a, but has significant side effects, show findings from a phase III trial.

12 Nov 2012

Nanofiber technique to build new nerves from stem cells

Every week in his clinic at the University of Michigan, neurologist Joseph Corey, M.D., Ph.D., treats patients whose nerves are dying or shrinking due to disease or injury.

8 Nov 2012

Degeneration of serotonergic neurons linked to spasticity in ALS

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with an occurrence rate in France similar to multiple sclerosis (two to three new cases per year for every 100,000 residents). It has a specific affect on neurons responsible for motor control, in particular motor neurones and central motor neurones. The former, located in the spinal cord, are directly linked to muscles and are used for muscle contraction and stretching.

7 Nov 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.

6 Nov 2012

Study reveals why MRI brain images are so sensitive to the direction in which nerve fibres run

World-leading experts in Magnetic Resonance Imaging from The University of Nottingham's Sir Peter Mansfield Magnetic Resonance Centre have made a key discovery which could give the medical world a new tool for the improved diagnosis and monitoring of brain diseases like multiple sclerosis.

4 Nov 2012

Researchers unlock complex cellular mechanics that instruct glial progenitor cells to divide

In a new study appearing this month in the Journal of Neuroscience, researchers have unlocked the complex cellular mechanics that instruct specific brain cells to continue to divide. This discovery overcomes a significant technical hurdle to potential human stem cell therapies; ensuring that an abundant supply of cells is available to study and ultimately treat people with diseases.

2 Nov 2012

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

A drug which was originally developed to treat leukaemia and other cancers of the immune system offers substantial improvements over existing treatments in reducing relapse rates for people with multiple sclerosis (MS), even when they have not responded well to first-line treatment, according to the results of two phase 3 trials published Online First in The Lancet.

1 Nov 2012

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2012.

1 Nov 2012

Blocking hyaluronidase activity can help repair brain damage associated with MS

Researchers at Oregon Health & Science University have discovered that blocking a certain enzyme in the brain can help repair the brain damage associated with multiple sclerosis and a range of other neurological disorders.

1 Nov 2012

Vitamin D and multiple sclerosis: an interview with Ellen Mowry

Vitamin D is actually a hormone. For the most part, humans obtain vitamin D through sun exposure. Ultraviolet light from the sun promotes the conversion of a compound in the skin to pre-vitamin D.

31 Oct 2012

Preeclampsia risk higher for women with Lupus

New research reports that women with systemic lupus erythematosus (SLE) have a two-fold increase in risk of preeclampsia—a dangerous condition in which pregnant women develop high blood pressure (hypertension) and protein in their urine (proteinuria) after 20 weeks of gestation

30 Oct 2012

Top-line results from Neuraltus’ NP001 Phase 2 study on amyotrophic lateral sclerosis

Neuraltus Pharmaceuticals, a private biopharmaceutical company developing novel therapies for rare neurological disorders, announced today top-line results from the Company's Phase 2 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).

30 Oct 2012

Sclerosis News and Research

Generic scale compares manual ability across diagnoses

Boston and Cincinnati Children's Hospital to learn more about how autism develops

New nanoparticle halts relapsing remitting multiple sclerosis in mouse model

NIH-funded scientists develop new treatment to combat autoimmune disorders in mouse model

Study shows how Parkinson's spreads and leads to nerve cell death

Caution over monoclonal antibody treatment for MS

Nanofiber technique to build new nerves from stem cells

Degeneration of serotonergic neurons linked to spasticity in ALS

Alnylam third quarter 2012 revenues decrease to $16.8 million

Study reveals why MRI brain images are so sensitive to the direction in which nerve fibres run

Researchers unlock complex cellular mechanics that instruct glial progenitor cells to divide

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Blocking hyaluronidase activity can help repair brain damage associated with MS

Vitamin D and multiple sclerosis: an interview with Ellen Mowry

Preeclampsia risk higher for women with Lupus

Top-line results from Neuraltus’ NP001 Phase 2 study on amyotrophic lateral sclerosis

Notable Medicare lawsuit settlement could aid patients needing skilled nursing care, other types of therapy

First Edition: October 29, 2012

Researchers use baker's yeast to identify new therapies for Lou Gehrig's disease

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News